Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2021

Summary of Significant Accounting Policies

Schedule of anti dilutive net loss per common shares

		Three Months Ended								Six Months Ended
		June 30, 2021				June 30, 2020				June 30, 2021				June 30, 2020

Numerator:

Net loss		$	(1,331,792	)		$	(821,649	)		$	(3,636,700	)		$	(2,242,822	)

Denominator:
Weighted-average basic and diluted common units/shares			1,911,009				1,911,009				1,911,009				1,911,009

Basic and diluted net loss per common unit/share		$	(0.70	)		$	(0.43	)		$	(1.90	)		$	(1.17	)

Schedule of potentially dilutive securities

		As of
		June 30, 2021				June 30, 2020

Series 1 Preferred Units/Shares			336,882				336,882
Series 1a Preferred Units/Shares			244,811				243,897
Series 1a Prerferred Warrant Units/Shares			69,212				70,126
Series 1b Preferred Units/Shares			317,058				317,058
Series 1c Preferred Units/Shares			2,270,866				2,270,866
Series 1d Preferred Shares			899,046				-
Class B Common Units Profits Interests			-				362,826
Common Stock Options			398,199				-
Common Stock Warrants			65,303				-
Total potentially dilutive securities			4,601,337				3,601,655